Sorted By Test Name - Mayo Medical Laboratories

HLLFH
34854
5434
molecular prognostic markers is necessary, is available. After this delay, the diagnostic sample is usually
no longer available or the nucleic acid has degraded to such an extent that it is no longer adequate for
testing. Thus, it is useful to obtain nucleic acid on such specimens promptly at diagnosis and retain it until
it is known whether additional testing is necessary.
Useful For: Reserving nucleic acid on any specimen for which molecular analysis may be necessary at
a future date, ensuring that adequate material for testing is available
Interpretation: A report of "Performed" will be sent and a $75 processing fee will be assessed. No
interpretation will be given. Should the sample be used in future testing, interpretation would be
incorporated with the final testing.
Reference Values:
Not applicable
Hematologic Disorders, Leukemia/Lymphoma; Flow Hold Varies
Clinical Information: Diagnostic hematopathology has become an increasingly complex
subspecialty, particularly with neoplastic disorders of blood and bone marrow. While morphologic
assessment of blood smears, bone marrow smears, and tissue sections remains the cornerstone of
lymphoma and leukemia diagnosis and classification, immunophenotyping is a very valuable and
important complementary tool. Immunophenotyping hematopoietic specimens can help resolve many
differential diagnostic problems posed by the clinical or morphologic features.
Useful For: Evaluating lymphocytoses of undetermined etiology Identifying B- and T-cell
lymphoproliferative disorders involving blood and bone marrow Distinguishing acute lymphoblastic
leukemia (ALL) from acute myeloid leukemia (AML) Immunologic subtyping of ALL Distinguishing
reactive lymphocytes and lymphoid hyperplasia from malignant lymphoma Distinguishing between
malignant lymphoma and acute leukemia Phenotypic subclassification of B- and T-cell chronic
lymphoproliferative disorders, including chronic lymphocytic leukemia, mantle cell lymphoma, and hairy
cell leukemia Recognizing AML with minimal morphologic or cytochemical evidence of differentiation
Recognizing monoclonal plasma cells
Interpretation: Report will include a morphologic description, a summary of the procedure, the
percent positivity of selected antigens, and an interpretive conclusion based on the correlation of the
clinical history with the morphologic features and immunophenotypic results.
Reference Values:
When performed, an interpretive report will be provided.
This test will be processed as a laboratory consultation. An interpretation of the immunophenotypic
findings and correlation with the morphologic features will be provided by a Hematopathologist.
Clinical References: 1. Hanson CA, Kurtin PJ, Katzman JA, et al: Immunophenotypic analysis of
peripheral blood and bone marrow in the staging of B-cell malignant lymphoma. Blood
1999;94:3889-3896 2. Hanson CA: Acute leukemias and myelodysplastic syndromes. In Clinical
Laboratory Medicine. Edited by KD McClatchey. Baltimore, MD, Williams & Wilkins, Inc, 1994, pp
939-969 3. Morice WG, Leibson PJ, Tefferi A: Natural killer cells and the syndrome of chronic natural
killer cell lymphocytosis. Leuk Lymphoma 2001;41(3-4):277-284 4. Langerak, van Den Beemd,
Wolvers-Tettero, et al: Molecular and flow cytometric analysis of the Vbeta repertoire for clonality
assessment in mature TCR alpha beta T-cell proliferations. Blood 2001;98(1):165-173
Hematopathology Consultation
Clinical Information: Diagnostic hematopathology has become an increasingly complex
subspecialty, particularly with neoplastic disorders of blood and bone marrow. The clinical, therapeutic,
and prognostic features of these disorders are often distinctive, while the pathologic features are quite
subtle, requiring the application of ancillary studies (eg, cytochemistry, immunohistochemistry, flow
cytometric immunophenotyping, cytogenetics, and molecular genetics) to establish a diagnosis.
Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 868